Ekaterina Yu. Aleynikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ekaterina Yu. Aleynikova has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alina V. Solovyeva
RUDN University
19 shared publications - M. A. Spitsyna
Peoples’ Friendship University of Russia named after Patrice Lumumba
11 shared publications Е. Ю. Алейникова
Российский университет дружбы народов имени Патриса Лумумбы
8 shared publications- Larisa Alekseevna Chegus
Khanty-Mansiysk State Medical Academy
7 shared publications - K. A. Gulenkova
Medical Institute, Peoples’ Friendship University of Russia named after Patrice Lumumba, Moscow
4 shared publications - Olga A. Kuznetsova
Peoples’ Friendship University of Russia
4 shared publications
Latest Publications
- Open Access
- 4 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 5,p. 145-151
Women’s health before and after myomectomy
Introduction. Recently, special attention has been paid to the quality of life of women and its changes after myomectomy.Aim. To assess the effect of myomectomy on menstrual function and quality of life in women with uterine fibroids.Materials and methods. A prospective clinical observational study was carried out at the clinical sites of the Department of Obstetrics and Gynecology with a course of perinatology at the Medical Institute of the RUDN University named after. Patrice Lumumba. Women of reproductive age with uterine fibroids (n = 80) and indications for organ-preserving treatment were selected, their complaints, general and obstetric-gynecological anamnesis, clinical, laboratory and instrumental studies of the patients were analyzed. The UFS-QOL questionnaire developed by the SIR Foundation was used to assess the severity of uterine fibroid symptoms and quality of life. Accumulation, adjustment, systematization of source information and statistical analysis were carried out using the IBM SPSS Statistics v. 23 program (IBM Corporation).Results. The average age of women with uterine fibroids was 40.36 ± 4.5 (27–49) years. During surgery, one myomatous node was removed in 61 (76.3%) women; in the rest, from 2 to 7 myomas were removed. Localization of removed fibroids according to the classification of The International Federation of Gynecology and Obstetrics 2018 (FIGO): in 3 (3.75%) women it was classified as type 7 according to FIGO – in 1 patient the node was isthmus, in 2 it was intraligamentous. The size of the identified fibroids varied from 0.5 cm to 15 cm (3.78 ± 3.0). 50% of patients with uterine fibroids had heavy menstruation, and 27.5% were diagnosed with iron deficiency anemia. When assessing the average severity of symptoms of uterine fibroids before and after myomectomy, it was found to decrease from 31.46 ± 20.0 (0–93.75) to 14.91 ± 17.1 (0–84.37) (p < 0.001). The HRQL total quality of life score also increased from 71.14 ± 20.7 (22.41–100) to 82.05 ± 17.6 (30.17–100) (p < 0.001). The number of women after myomectomy with a total HRQL level of more than 75 increased statistically significantly by 27.5% and decreased by 20% in the range of 50–75 (p < 0.05). However, when analyzing the results of the UFS-QOL questionnaires, it was found that in 7 (8.75%) patients the quality of life did not change before and after myomectomy, and in 12 (15%) women, despite a decrease in the severity of symptoms of uterine fibroids after myomectomy, quality of life (HRQL total) became slightly lower (Wilcoxon test 129.5, p = 0.242). 6 (7.5%) women experienced worsening symptoms of uterine fibroids after surgery: 25.52 ± 11.4 (9.38–43.75) before myomectomy and 33.33 ± 13.6 (12.5–50) after (Wilcoxon test 30, p = 0.146).Conclusions. Myomectomy did not always lead to healthier women and an improvement in their quality of life. Further research in this area is required.
- 4 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 5,p. 145-151
Open AccessWomen’s health before and after myomectomy
Introduction. Recently, special attention has been paid to the quality of life of women and its changes after myomectomy.Aim. To assess the effect of myomectomy on menstrual function and quality of life in women with uterine fibroids.Materials and methods. A prospective clinical observational study was carried out at the clinical sites of the Department of Obstetrics and Gynecology with a course of perinatology at the Medical Institute of the RUDN University named after. Patrice Lumumba. Women of reproductive age with uterine fibroids (n = 80) and indications for organ-preserving treatment were selected, their complaints, general and obstetric-gynecological anamnesis, clinical, laboratory and instrumental studies of the patients were analyzed. The UFS-QOL questionnaire developed by the SIR Foundation was used to assess the severity of uterine fibroid symptoms and quality of life. Accumulation, adjustment, systematization of source information and statistical analysis were carried out using the IBM SPSS Statistics v. 23 program (IBM Corporation).Results. The average age of women with uterine fibroids was 40.36 ± 4.5 (27–49) years. During surgery, one myomatous node was removed in 61 (76.3%) women; in the rest, from 2 to 7 myomas were removed. Localization of removed fibroids according to the classification of The International Federation of Gynecology and Obstetrics 2018 (FIGO): in 3 (3.75%) women it was classified as type 7 according to FIGO – in 1 patient the node was isthmus, in 2 it was intraligamentous. The size of the identified fibroids varied from 0.5 cm to 15 cm (3.78 ± 3.0). 50% of patients with uterine fibroids had heavy menstruation, and 27.5% were diagnosed with iron deficiency anemia. When assessing the average severity of symptoms of uterine fibroids before and after myomectomy, it was found to decrease from 31.46 ± 20.0 (0–93.75) to 14.91 ± 17.1 (0–84.37) (p < 0.001). The HRQL total quality of life score also increased from 71.14 ± 20.7 (22.41–100) to 82.05 ± 17.6 (30.17–100) (p < 0.001). The number of women after myomectomy with a total HRQL level of more than 75 increased statistically significantly by 27.5% and decreased by 20% in the range of 50–75 (p < 0.05). However, when analyzing the results of the UFS-QOL questionnaires, it was found that in 7 (8.75%) patients the quality of life did not change before and after myomectomy, and in 12 (15%) women, despite a decrease in the severity of symptoms of uterine fibroids after myomectomy, quality of life (HRQL total) became slightly lower (Wilcoxon test 129.5, p = 0.242). 6 (7.5%) women experienced worsening symptoms of uterine fibroids after surgery: 25.52 ± 11.4 (9.38–43.75) before myomectomy and 33.33 ± 13.6 (12.5–50) after (Wilcoxon test 30, p = 0.146).Conclusions. Myomectomy did not always lead to healthier women and an improvement in their quality of life. Further research in this area is required.
- Open Access
- 26 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 44-51
The course of pregnancy and childbirth in women with iron deficiency anemia treated with iron (II) sulfate and not treated
Introduction. Due to the plasma volume expansion prevailing over the increase in red blood cell production, as well as inadequate dietary intake with underlying physiologically increased iron requirements, pregnant women tend to suffer from iron deficiency and anaemia.Aim. To evaluate the efficacy of Tardyferon (depot iron (II) sulphate 80 mg) in pregnant women with anaemia in reducing adverse perinatal outcomes. Materials and methods. To conduct the retrospective chart review of pregnant women of Stavropol Krai, the patients were divided into 2 groups: Group 1 (n = 70) – the treatment group, which included pregnant women who were diagnosed with IDA in the 1st, 2nd or 3rd trimesters and who received antianemic therapy, and Group 2 (n = 30) – pregnant women with IDA (diagnosed in the 3rd trimester) who did not use any iron supplements.Results. In Group I, haemoglobin levels identified at the time of detection of anaemia ranged from 91 to 109 g/l (103.1 ± 4.5), red blood cell counts from 2.7 to 4.1 × 109/l (3.5 ± 0.3), and hematocrit levels from 26 to 37 (32.9 ± 1.8). Once the diagnosis of anaemia had been established, pregnant women were prescribed with Tardiferon 80 mg twice a day, which they administered on a regular basis until delivery and continued using during the postpartum period. In Group 2, patients did not receive any iron supplements and showed a gradual decrease in haemoglobin levels by an average of 5.6 g/l. Pregnant women receiving Tardyferon prolonged-release tablets from the date when anaemia was diagnosed showed an increase in clinical blood test values.Conclusions. In pregnant women with anaemia, iron therapy normalizes haematological parameters, which leads to improved tissue oxygen supply and a favourable clinical effect.
- 26 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 44-51
Open AccessThe course of pregnancy and childbirth in women with iron deficiency anemia treated with iron (II) sulfate and not treated
Introduction. Due to the plasma volume expansion prevailing over the increase in red blood cell production, as well as inadequate dietary intake with underlying physiologically increased iron requirements, pregnant women tend to suffer from iron deficiency and anaemia.Aim. To evaluate the efficacy of Tardyferon (depot iron (II) sulphate 80 mg) in pregnant women with anaemia in reducing adverse perinatal outcomes. Materials and methods. To conduct the retrospective chart review of pregnant women of Stavropol Krai, the patients were divided into 2 groups: Group 1 (n = 70) – the treatment group, which included pregnant women who were diagnosed with IDA in the 1st, 2nd or 3rd trimesters and who received antianemic therapy, and Group 2 (n = 30) – pregnant women with IDA (diagnosed in the 3rd trimester) who did not use any iron supplements.Results. In Group I, haemoglobin levels identified at the time of detection of anaemia ranged from 91 to 109 g/l (103.1 ± 4.5), red blood cell counts from 2.7 to 4.1 × 109/l (3.5 ± 0.3), and hematocrit levels from 26 to 37 (32.9 ± 1.8). Once the diagnosis of anaemia had been established, pregnant women were prescribed with Tardiferon 80 mg twice a day, which they administered on a regular basis until delivery and continued using during the postpartum period. In Group 2, patients did not receive any iron supplements and showed a gradual decrease in haemoglobin levels by an average of 5.6 g/l. Pregnant women receiving Tardyferon prolonged-release tablets from the date when anaemia was diagnosed showed an increase in clinical blood test values.Conclusions. In pregnant women with anaemia, iron therapy normalizes haematological parameters, which leads to improved tissue oxygen supply and a favourable clinical effect.
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 13 (s)
Prediction of induced preterm labor in early severe preeclampsia
Прогнозирование индуцированных преждевременных родов при ранней тяжелой преэклампсии
- 1 January 2025
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 13 (s)
Open AccessPrediction of induced preterm labor in early severe preeclampsia
Прогнозирование индуцированных преждевременных родов при ранней тяжелой преэклампсии
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 13 (s)
Rational start of menopausal hormonal therapy: time, place, possibilities. Review of evidence
Рациональный старт менопаузальной гормональной терапии: время, место, возможности. Обзор доказательных данных
- 1 January 2025
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 13 (s)
Open AccessRational start of menopausal hormonal therapy: time, place, possibilities. Review of evidence
Рациональный старт менопаузальной гормональной терапии: время, место, возможности. Обзор доказательных данных
- Open Access
- 7 November 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 47-51
Iron deficiency anemia and anemia of chronic disease – what is known?
Anemia is the most common disease in the world, affecting about 30–40% of people. Children, adolescents, and women are most often affected by anemia. The main causes of true iron deficiency (ID and IDA) are insufficient iron intake, increased iron loss (chronic bleeding), increased iron requirement, and impaired iron absorption (gastrointestinal diseases). Chronic diseases, inflammatory conditions, autoimmune diseases, obesity cause an increase in the synthesis of hepcidin in the liver and block the entry of iron into the bloodstream, leading to functional iron deficiency. Anemia of chronic diseases (ACD) or anemia of chronic inflammation (the second most common anemia) is associated with the fact that iron is present in the body, but the absorption of iron in various areas is limited. Until recently, it was believed that treatment with iron supplements in the absence of iron deficiency does not bring benefit to patients with ACD. The opinion has been repeatedly expressed about the harm of iron therapy, since iron is necessary for the growth of some pathogenic microorganisms and tumor cells. However, the real clinical significance of these mainly theoretical provisions is unknown. Therefore, the prescription of iron preparations for anemia is justified and logical. Ferrous sulfate (ferrous iron) is most often prescribed orally due to its low cost, high bioavailability and effectiveness. The drug Tardiferon, containing iron sulphate 247.25 mg (in terms of iron (II) 80.00 mg), is widely used in patients with IDA and ID, since divalent iron has a high ability to overcome the intestinal barrier by “passive” transport and quickly create high concentrations in the blood, restoring the level of hemoglobin and iron stores in the body. The drug Tardiferon has a relatively low dose of iron – 80 mg with slow-release technology to avoid irritating effects on the intestine, contributing to good tolerability. A number of studies confirmed a high safety profile – patients did not refuse to take the drug due to side effects. Timely examination and identification of patients with anemia allows you to prescribe an effective correction. The drug Tardiferon promotes rapid restoration of hemoglobin and iron stores in the body and has good tolerability.
- 7 November 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 47-51
Open AccessIron deficiency anemia and anemia of chronic disease – what is known?
Anemia is the most common disease in the world, affecting about 30–40% of people. Children, adolescents, and women are most often affected by anemia. The main causes of true iron deficiency (ID and IDA) are insufficient iron intake, increased iron loss (chronic bleeding), increased iron requirement, and impaired iron absorption (gastrointestinal diseases). Chronic diseases, inflammatory conditions, autoimmune diseases, obesity cause an increase in the synthesis of hepcidin in the liver and block the entry of iron into the bloodstream, leading to functional iron deficiency. Anemia of chronic diseases (ACD) or anemia of chronic inflammation (the second most common anemia) is associated with the fact that iron is present in the body, but the absorption of iron in various areas is limited. Until recently, it was believed that treatment with iron supplements in the absence of iron deficiency does not bring benefit to patients with ACD. The opinion has been repeatedly expressed about the harm of iron therapy, since iron is necessary for the growth of some pathogenic microorganisms and tumor cells. However, the real clinical significance of these mainly theoretical provisions is unknown. Therefore, the prescription of iron preparations for anemia is justified and logical. Ferrous sulfate (ferrous iron) is most often prescribed orally due to its low cost, high bioavailability and effectiveness. The drug Tardiferon, containing iron sulphate 247.25 mg (in terms of iron (II) 80.00 mg), is widely used in patients with IDA and ID, since divalent iron has a high ability to overcome the intestinal barrier by “passive” transport and quickly create high concentrations in the blood, restoring the level of hemoglobin and iron stores in the body. The drug Tardiferon has a relatively low dose of iron – 80 mg with slow-release technology to avoid irritating effects on the intestine, contributing to good tolerability. A number of studies confirmed a high safety profile – patients did not refuse to take the drug due to side effects. Timely examination and identification of patients with anemia allows you to prescribe an effective correction. The drug Tardiferon promotes rapid restoration of hemoglobin and iron stores in the body and has good tolerability.
- Open Access
- 9 May 2024
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 26 (1) , 76-82
Uterine artery embolization in the treatment of uterine fibroids and the preservation of reproductive health in women 40 years of age and older: A retrospective study
Aim. To evaluate the effect of uterine artery embolization (UAE) on reproductive health in women 40 years and older. Materials and methods. A retrospective study was conducted at the perinatal center of the District Clinical Hospital of Khanty-Mansiysk. Patients were divided into two groups: the main group (group 1; n=57) included women with uterine fibroids after UAE, and the control group (group 2; n=42) included women without a history of uterine fibroids. Results. Women with uterine fibroids were statistically more likely to have grade 1 obesity (χ2=4.39; p=0.04) and less likely to have normal body weight (χ2=8.73; p=0.00) compared to women without fibroids. Smoking increased the risk of uterine fibroids twofold (χ2=4.49; p=0.03; odds ratio 1.97; confidence interval 0.64-6.11). More women with uterine fibroids had a history of abortions (n=42; 73.7%) than those without uterine fibroids (n=19; 45.2%; χ2=8.27; p=0.01). The most common gynecological comorbidities in women with uterine fibroids included inflammatory disease of the uterus (N71), endometrial polyp (N84), and endometriosis (N80); p0.05. The most common extragenital diseases in patients with uterine fibroids included thyroid disease, hypertension, and iron deficiency anemia (p0.05). Contour SE embolization agent with spherical particles was more often associated with pain (χ2=0.18; p=0.67) and less often with fever (χ2=4.47; p=0.03). There was a decrease in the number of short menstrual cycles (less than 24 days) from the moment before surgical treatment and after 24 months (χ2=34.580; p0.001) and an increase in the number of cycles of 24–38 days (χ2=14.887; p=0.005). At 24 months after UAE, there were more women with a menstrual period of less than 3 days (χ2=10.385; p=0.035) and fewer with a menstrual period of more than 8 days (χ2=34.573; p0.001). Ultrasound showed a decreased ovarian reserve at 6, 12 and 24 months after UAE (p0.05). Conclusion. When assessing the reproductive health of women 40 years and older after embolization of the uterine arteries, it was found that this method of treatment of symptomatic uterine fibroids leads to a decrease in the duration and heaviness of menstruation but increases the risk of an ovarian reserve decrease.
- 9 May 2024
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 26 (1) , 76-82
Open AccessUterine artery embolization in the treatment of uterine fibroids and the preservation of reproductive health in women 40 years of age and older: A retrospective study
Aim. To evaluate the effect of uterine artery embolization (UAE) on reproductive health in women 40 years and older. Materials and methods. A retrospective study was conducted at the perinatal center of the District Clinical Hospital of Khanty-Mansiysk. Patients were divided into two groups: the main group (group 1; n=57) included women with uterine fibroids after UAE, and the control group (group 2; n=42) included women without a history of uterine fibroids. Results. Women with uterine fibroids were statistically more likely to have grade 1 obesity (χ2=4.39; p=0.04) and less likely to have normal body weight (χ2=8.73; p=0.00) compared to women without fibroids. Smoking increased the risk of uterine fibroids twofold (χ2=4.49; p=0.03; odds ratio 1.97; confidence interval 0.64-6.11). More women with uterine fibroids had a history of abortions (n=42; 73.7%) than those without uterine fibroids (n=19; 45.2%; χ2=8.27; p=0.01). The most common gynecological comorbidities in women with uterine fibroids included inflammatory disease of the uterus (N71), endometrial polyp (N84), and endometriosis (N80); p0.05. The most common extragenital diseases in patients with uterine fibroids included thyroid disease, hypertension, and iron deficiency anemia (p0.05). Contour SE embolization agent with spherical particles was more often associated with pain (χ2=0.18; p=0.67) and less often with fever (χ2=4.47; p=0.03). There was a decrease in the number of short menstrual cycles (less than 24 days) from the moment before surgical treatment and after 24 months (χ2=34.580; p0.001) and an increase in the number of cycles of 24–38 days (χ2=14.887; p=0.005). At 24 months after UAE, there were more women with a menstrual period of less than 3 days (χ2=10.385; p=0.035) and fewer with a menstrual period of more than 8 days (χ2=34.573; p0.001). Ultrasound showed a decreased ovarian reserve at 6, 12 and 24 months after UAE (p0.05). Conclusion. When assessing the reproductive health of women 40 years and older after embolization of the uterine arteries, it was found that this method of treatment of symptomatic uterine fibroids leads to a decrease in the duration and heaviness of menstruation but increases the risk of an ovarian reserve decrease.
- Open Access
- 2 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 119-125
Pregravid preparation for women with bacterial vaginosis and a history of early pregnancy loss
Introduction. Statistics show that about 13 to 15 in 100 pregnancies end in early miscarriage. This represents both a medical and social issue, as such outcome may be associated with maternal depression and anxiety, which inevitably affects women’s activities, performance efficiency and social inclusion. Restoration of normobiocenosis and lactobacilli pool dominance is one of the key challenges for women planning pregnancy.Aim. To evaluate the effectiveness of probiotics at the pregravid preparation stage in women with a history of early pregnancy loss and bacterial vaginosis (BV).Materials and methods. We selected 46 patients of reproductive age (24–39 years) who applied for early pregnancy loss, with complaints of vaginal discharge with an unpleasant odour, pruritus, burning, and dyspareunia, using databases of 5 medical clinics in Moscow, Tyumen and Stavropol. To treat bacterial vaginosis, two-stage therapy aimed at eliminating the increased number of anaerobic microorganisms and restoring the vaginal microbiocenosis was used.Results. The effectiveness of combination therapy was assessed at 1 month. All patients on therapy experienced clinical improvement, normalization of vaginal microbiocenosis parameters based on Femoflor-16 test findings after the end of treatment. Physiological microbiocenosis of Lactobacillus spp. > 107 was detected in 43 (94.5%). In all patients, the average vaginal pH after two-stage therapy was 4.3 ± 0.7. The safety of Acilact Duo therapy was assessed in all study participants. No negative trends were recorded.Conclusion. Superlimflife (Acilact Duo), acidophilus bacteria + vitamin-mineral protein-peptide complex, quickly restores optimal vaginal acidity (pH), stimulates the growth of lactobacilli, and reduces the incidence of BV relapses.
- 2 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 119-125
Open AccessPregravid preparation for women with bacterial vaginosis and a history of early pregnancy loss
Introduction. Statistics show that about 13 to 15 in 100 pregnancies end in early miscarriage. This represents both a medical and social issue, as such outcome may be associated with maternal depression and anxiety, which inevitably affects women’s activities, performance efficiency and social inclusion. Restoration of normobiocenosis and lactobacilli pool dominance is one of the key challenges for women planning pregnancy.Aim. To evaluate the effectiveness of probiotics at the pregravid preparation stage in women with a history of early pregnancy loss and bacterial vaginosis (BV).Materials and methods. We selected 46 patients of reproductive age (24–39 years) who applied for early pregnancy loss, with complaints of vaginal discharge with an unpleasant odour, pruritus, burning, and dyspareunia, using databases of 5 medical clinics in Moscow, Tyumen and Stavropol. To treat bacterial vaginosis, two-stage therapy aimed at eliminating the increased number of anaerobic microorganisms and restoring the vaginal microbiocenosis was used.Results. The effectiveness of combination therapy was assessed at 1 month. All patients on therapy experienced clinical improvement, normalization of vaginal microbiocenosis parameters based on Femoflor-16 test findings after the end of treatment. Physiological microbiocenosis of Lactobacillus spp. > 107 was detected in 43 (94.5%). In all patients, the average vaginal pH after two-stage therapy was 4.3 ± 0.7. The safety of Acilact Duo therapy was assessed in all study participants. No negative trends were recorded.Conclusion. Superlimflife (Acilact Duo), acidophilus bacteria + vitamin-mineral protein-peptide complex, quickly restores optimal vaginal acidity (pH), stimulates the growth of lactobacilli, and reduces the incidence of BV relapses.
- Open Access
- 1 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 48-55
Courses of pregnancy in women witha uterine scar after conservative myomectomy
Introduction. Uterine fibroids are the most common disease of the female reproductive system. If indicated, the main organpreserving method of treatment is myomectomy. However, according to many researchers, women who have undergone conservative myomectomy are at a higher risk of developing complications during pregnancy such as placenta previa, placental disorders, and uterine scar failure.Aim. To identify the features of the course of pregnancy, childbirth and perinatal outcome in women with a uterine scar after conservative myomectomy who received pregravid preparation.Materials and methods. A retrospective study included an analysis of 159 outpatient histories of women planning pregnancy after conservative myomectomy, including the birth histories of 109 pregnant women aged 29–40 years who delivered at the Perinatal Center of the Regional Clinical Hospital in Khanty-Mansiysk from 2011 to 2021 in order to study the characteristics of the course of pregnancy in women with a scar on the uterus after conservative myomectomy.Results. When analyzing the data, the following statistically significant differences between the groups were revealed: the first trimester of pregnancy in women with a uterine scar compared with the control group was more often complicated by chorion presentation, threatened miscarriage, urinary tract infection and early toxicosis (p < 0.05); in the second trimester of pregnancy in group 1, there were more often threatening preterm labor and placental disorders (p < 0.05), the majority of women with a scar on the uterus after myomectomy (77.8%) were delivered by caesarean section, in contrast to the control group (9.7%) (p < 0.05).Conclusion. The data we obtained on the course of pregnancy, childbirth and perinatal outcomes after myomectomy reflected the need and effectiveness of preconception preparation in this contingent of women.
- 1 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 48-55
Open AccessCourses of pregnancy in women witha uterine scar after conservative myomectomy
Introduction. Uterine fibroids are the most common disease of the female reproductive system. If indicated, the main organpreserving method of treatment is myomectomy. However, according to many researchers, women who have undergone conservative myomectomy are at a higher risk of developing complications during pregnancy such as placenta previa, placental disorders, and uterine scar failure.Aim. To identify the features of the course of pregnancy, childbirth and perinatal outcome in women with a uterine scar after conservative myomectomy who received pregravid preparation.Materials and methods. A retrospective study included an analysis of 159 outpatient histories of women planning pregnancy after conservative myomectomy, including the birth histories of 109 pregnant women aged 29–40 years who delivered at the Perinatal Center of the Regional Clinical Hospital in Khanty-Mansiysk from 2011 to 2021 in order to study the characteristics of the course of pregnancy in women with a scar on the uterus after conservative myomectomy.Results. When analyzing the data, the following statistically significant differences between the groups were revealed: the first trimester of pregnancy in women with a uterine scar compared with the control group was more often complicated by chorion presentation, threatened miscarriage, urinary tract infection and early toxicosis (p < 0.05); in the second trimester of pregnancy in group 1, there were more often threatening preterm labor and placental disorders (p < 0.05), the majority of women with a scar on the uterus after myomectomy (77.8%) were delivered by caesarean section, in contrast to the control group (9.7%) (p < 0.05).Conclusion. The data we obtained on the course of pregnancy, childbirth and perinatal outcomes after myomectomy reflected the need and effectiveness of preconception preparation in this contingent of women.
- Open Access
- 1 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 92-97
Iron deficiency in pregnant women: effect on offspring neuropsychic development
Increasing evidence indicates that adversities in utero and early childhood can have long-lasting effects on physiological and mental health not only in childhood but also in adulthood. Micronutrient deficiency, and in particular iron deficiency, is one of the most significant factors. Based on literature data, to determine the effect of iron deficiency in pregnant women on the neuropsychological development of infants, as well as to determine a cohort of pregnant women who need iron supplements. The search was conducted in MEDLINE (from PubMed), EMBASE (from OVID), Cochrane Library and ClinicalTrials.gov from 2010 to December 2023 without language restrictions. Data were extracted. Primary outcomes included iron deficiency, serum ferritin less than 15 μg/L in pregnant women, perinatal outcomes, and development of children in infancy. The data of serum ferritin in umbilical cord blood in newborns were compared with the serum ferritin of mothers. Data on iron supplementation and its effect on perinatal outcomes were assessed. Daily oral iron supplementation during pregnancy in women without IDA or ID reduces the incidence of iron deficiency anemia at the woman’s due date, reduces the incidence of iron deficiency in fullterm neonates, and reduces the incidence of morbidity in low-birth-weight infants. Iron supplementation during pregnancy and the postpartum period is a strategy for timely replenishment of ID and prevention of IDA to reduce cerebral iron deficiency in the fetus and newborn. The absence of side effects and high bioavailability, enhanced by ascorbic acid, allow us to recommend SunActive®Fe Bonoferlat as a daily supplement for pregnant and lactating women, according to WHO recommendations.
- 1 May 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 92-97
Open AccessIron deficiency in pregnant women: effect on offspring neuropsychic development
Increasing evidence indicates that adversities in utero and early childhood can have long-lasting effects on physiological and mental health not only in childhood but also in adulthood. Micronutrient deficiency, and in particular iron deficiency, is one of the most significant factors. Based on literature data, to determine the effect of iron deficiency in pregnant women on the neuropsychological development of infants, as well as to determine a cohort of pregnant women who need iron supplements. The search was conducted in MEDLINE (from PubMed), EMBASE (from OVID), Cochrane Library and ClinicalTrials.gov from 2010 to December 2023 without language restrictions. Data were extracted. Primary outcomes included iron deficiency, serum ferritin less than 15 μg/L in pregnant women, perinatal outcomes, and development of children in infancy. The data of serum ferritin in umbilical cord blood in newborns were compared with the serum ferritin of mothers. Data on iron supplementation and its effect on perinatal outcomes were assessed. Daily oral iron supplementation during pregnancy in women without IDA or ID reduces the incidence of iron deficiency anemia at the woman’s due date, reduces the incidence of iron deficiency in fullterm neonates, and reduces the incidence of morbidity in low-birth-weight infants. Iron supplementation during pregnancy and the postpartum period is a strategy for timely replenishment of ID and prevention of IDA to reduce cerebral iron deficiency in the fetus and newborn. The absence of side effects and high bioavailability, enhanced by ascorbic acid, allow us to recommend SunActive®Fe Bonoferlat as a daily supplement for pregnant and lactating women, according to WHO recommendations.
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 12 (3)
Severe preeclampsia. Clinical and anamnestic characteristics of women with induced preterm labor
Тяжелая преэклампсия. Клинико-анамнестическая характеристика женщин с индуцированными преждевременными родами
- 1 January 2024
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 12 (3)
Open AccessSevere preeclampsia. Clinical and anamnestic characteristics of women with induced preterm labor
Тяжелая преэклампсия. Клинико-анамнестическая характеристика женщин с индуцированными преждевременными родами